Study details
Enrolling now
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
NCT IDNCT06090266ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
168
Study length
about 3.3 years
Ages
18+
Locations
4 sites in TX, VA
About this study
Researchers are testing the safety and effectiveness of OR502, a monoclonal antibody, alone or with cemiplimab, in people with advanced solid tumors. The trial will last for about 1 year and involve approximately 168 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cemiplimab
- 2.Take OR502
PhasePhase 1/Phase 2
DrugCemiplimab
Primary goalAdverse Events and Serious Adverse Events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cemiplimab
Endpoints
Primary: Adverse Events and Serious Adverse Events, Dose-limiting Toxicity
Secondary: Disease Control Rate (DCR), Objective Response Rate (ORR), Pharmacokinetics of OR502, Progression Free Survival (PFS)
Body systems
Oncology